Nuvama’s Take On The Renewed Biosecure Act
About Nuvama
Nuvama is a full-service Indian financial services group offering equity research, broking, investment banking and advisory solutions to institutional and retail clients. Its research team regularly publishes sector studies and actionable ideas for investors and traders.
Key Points From The Note
- The Biosecure Act is back on the U.S. legislative agenda in a fresh draft form.
- This new draft appears to be a diluted version compared with the earlier proposal.
- If enacted, the law could bar certain biotechnology firms of concern — notably companies with Chinese ties — from participating in some activities.
- The bill includes a separate list of covered companies, but the draft does not explicitly reference Wuxi group companies.
What Happened Previously
When a prior version of the Biosecure Act was debated (but not passed), it triggered extra due diligence requests and helped Indian CDMOs win more projects from Western innovators looking to diversify supply chains.
Potential Impact
A renewed push for the Act could re-focus global innovators on supply-chain security and onshoring alternatives. That shift may again create demand opportunities for credible Indian CDMOs and related suppliers.
Nuvama’s Recommendation (CDMO Coverage)
Nuvama reiterates a BUY stance across its covered contract development & manufacturing organisations (CDMOs). Key calls and Nuvama’s target prices are listed below:
- Divi’s Laboratories — Target Price ₹7,110
- Neuland Laboratories — Target Price ₹17,700
- Jubilant Pharmova — Target Price ₹1,500
For Traders
For traders looking to navigate sector moves and short-term volatility, consider the research-backed tips below:
📌 Read complimentary insights at Indian-Share-Tips.com, a SEBI Registered Advisory Services.
Investor Takeaway
The revived Biosecure Act — even in a diluted form — keeps supply-chain security on policymakers’ and corporates’ radars. Investors focused on pharmaceutical supply chains should watch CDMOs with strong compliance, diversified client bases and scalable manufacturing; these names may see renewed inflows as global firms accelerate de-risking strategies.
Disclaimer
This content is for informational purposes only and does not constitute investment advice. Readers should perform their own due diligence or consult a SEBI-registered advisor before acting on any information in this post.
